Clinical Trial

R-2487 in Patients With Rheumatoid Arthritis

Study acronym: R-2487-RA01
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-07-18; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Recruiting 2023-10-19
Trial Details
NCT Number NCT05961592
Lead Sponsor Rise Therapeutics LLC
Conditions Arthritis, Rheumatoid
Enrollment 73 participants
Start Date 2023-10-19
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-12